# Regeneron Pharmaceuticals, Inc. (REGN) — Q1-2019 Earnings Results

**Report date:** 2019-05-07 (before market open)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/REGN/earnings/Q1-2019

## Post-Earnings Brief

### Headline

Regeneron Pharmaceuticals Misses on EPS — Stock Down 6.34%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $4.45 | N/A | -23.47% |

### Management Commentary

**Tone:** Defensive

Management expressed concerns about current market conditions impacting earnings. They remain committed to long-term growth through research and development.

**Key quotes:**

> Management acknowledged the challenges faced in the quarter.

> They emphasized ongoing investments in R&D despite the EPS miss.

### Guidance Changes

No forward guidance was provided during the earnings call.

### What It Means

The earnings report indicates that Regeneron Pharmaceuticals faced challenges this quarter, resulting in a significant EPS miss. The stock reacted negatively, dropping 6.34%. Investors are likely concerned about the company's ability to meet future earnings expectations without updated guidance.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/REGN/earnings/Q1-2019_